Back to results
US 2010/0075960 A1Published application
Benzimidazole thiophene compounds
OwnerKevin Kuntz, Kyle Allen Emmitte +5inventors
InventorsKevin Kuntz, Kyle Allen Emmitte, Tara Renae Rheault, Stephon Smith, Keith Hornberger, Hamilton Dickson, Mui Cheung
Life of this patent
Estimating the term…
Abstract
The present invention provides bezimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Claims26
A compound of formula (I):
- wherein:
- R1 is selected from H, halo, alkyl, haloalkyl, —OR7, —CN, —C(O)NR7R8, —S(O)2R7, —R5—S(O)2R7, —NR7R8, —NR7C(O)R8, Ph, and Het1;
- Ph is phenyl optionally substituted 1 or 2 times with halo, alkyl, haloalkyl, —OR7, —CN, —S(O)2R7 and —NR7R8;
- Het1 is a 5-6 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S, optionally substituted 1 or 2 times with a substituent selected from halo, alkyl, haloalkyl, —OR7, —CN, —S(O)2R7, —NR7R8, Het2, —R5-Het2, NR7-Het2, and oxo;
- Het2 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S, optionally substituted 1 or 2 times with a substituent selected from alkyl, —OR7, —NR7R8, —C(O)NR7R8, —S(O)2R7, and oxo;
- R2 is selected from H, halo, alkyl, haloalkyl, —OR7, —CN, —C(O)NR7R8, —S(O)2R7, —R5—S(O)2R7, —S(O)2NR7R8, —R5—S(O)2NR7R8, —NR7R8, and —NR7C(O)R8;
- R3 is H, alkyl or haloalkyl;
- Z1, Z2 and Z3 are each the same or different and are independently C, CH or N, wherein at least one of Z1, Z2 and Z3 is C or CH;
- d is 0, 1 or 2;
- each R4 is the same or different and is independently halo, alkyl or haloalkyl;
- Y1 is —O— or —N(R7)—;
- a is 0 or 1;
- each R5 is the same or different and is independently C1-3alkylene;
- Ring A is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S;
- b is 0, 1 or 2;
- each R6 is the same or different and is independently selected from halo, alkyl, haloalkyl, alkenyl, —CN, —R5—CN, —CO2R7, —R5—CO2R7, —C(O)NR7R8, —R5—C(O)NR7R8, —OR7, —R6—OR7, —S(O)2R7, —R5—S(O)2R7, —S(O)2NR7R8, —R5—S(O)2NR7R8, —NR7R8, —R5—NR7R8, —NR7C(O)R8, —NR7S(O)2R8, —NR7C(O)NR7R8, —NR7C(O)2R8 and oxo;
- each R7 and each R8 are the same or different and are each independently selected from H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, cycloalkyl and cycloalkenyl;
- and pharmaceutically acceptable salts thereof.
15 more elements
An enantiomerically enriched compound of formula (XL):
- wherein:
- R1 is selected from H, halo, alkyl, haloalkyl, —OR7, —CN, —C(O)NR7R8, —S(O)2R7, —R5—S(O)2R7 and Het1;
- Het1 is a 5-6 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S, optionally substituted 1 or 2 times with a substituent selected from alkyl, haloalkyl, —OR7, —CN, —S(O)2R7, —NR7R8 and oxo;
- R2 is selected from H, halo, alkyl, haloalkyl, —OR7, —CN, —C(O)NR7R8, —S(O)2R7, —R5—S(O)2R7, —S(O)2NR7R8, —R5—S(O)2NR7R8, —NR7R8, and —NR6C(O)R8;
- R3 is alkyl;
- * indicates a chiral carbon;
- R4 is H or halo;
- each R5 is the same or different and is independently C1-3alkylene;
- Ring A is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N, O and S;
- b is 0 or 1;
- each R6 is the same or different and is independently selected from halo, alkyl, haloalkyl, —CO2R7, —R5—CO2R7, —OR7, —R5—OR7, —S(O)2R7, —R8—S(O)2R7, —NR7R8, —R8—NR7R8 and oxo;
- each R7 and each R8 are the same or different and are each independently selected from H, alkyl and haloalkyl;
- or a pharmaceutically acceptable salt thereof.
10 more elements
(canceled)
22-31. (canceled)
35-42. (canceled)
Dependencies are inferred from the claim text.